January 13, 2005 -- In filing its first IND application this month, StemCells took a giant leap forward, both for the company, and symbolically, for the entire stem-cell line of pharmaceutical inquiry. The company proposes to inject purified human neural stem cells into the brains of children and infants who suffer from Batten’s disease, a rare, but fatal disorder striking infants and children characterized by seizures and loss in motor ability, sight and mental function. We discuss the company’s future, its science and its finances.
